Archive · 17 Jun 2025
Nomura's Analysis: Sun Pharma Faces Challenges, Limited Upside
Imagine a company called Sun Pharma that makes medicine.
A financial company called Nomura looked at Sun Pharma and doesn't think its stock price will go up much.
They're worried about a factory, Halol, because it has some problems.
Inspectors found issues, and the factory needs to fix them.
Even if the factory gets better, it won't help the stock price a lot.
The company is also changing who is in charge, but that's not expected to change the stock price.
Since the stock has already done well, Nomura thinks it won't go up much more.
Nomura maintains a 'Neutral' rating on Sun Pharma due to concerns about the Halol facility.
The USFDA issued eight observations to the Halol plant after a recent inspection.
Clearance of the Halol site is expected to have a marginal positive impact, with approximately $50 million in revenue potential.
Management changes are underway, with Kirti Ganorkar becoming Managing Director and Dilip Shanghvi moving to Executive Chairman.
Sun Pharma's stock has already risen significantly since an import alert in 2022, limiting further upside.
- Who
- Nomura and Sun Pharma.
- What
- Nomura's analysis of Sun Pharma's stock.
- When
- The analysis was released recently after USFDA inspection.
- Where
- The analysis focuses on Sun Pharma's Halol facility.
- Why
- Nomura sees limited upside potential due to regulatory concerns and existing stock performance.
Nomura's Concerns
Market Outlook
Halol Facility
Nomura's Concerns
Clearance of Halol plant may not significantly boost stock.
Market Outlook
Potential for production and sales increase.
- Company
- Sun Pharma
- Rating
- Neutral
- Target Price
- Rs 1,970 per share
- Upside Potential
- 17%
- Halol Observations
- Eight
- Revenue Potential (Halol)
- $50 million
- Executive Chairman
- Dilip Shanghvi
- Managing Director
- Kirti Ganorkar